Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

por Bank, P. C. D., Swen, J. J., Guchelaar, H. J.
Publicado 2019

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

por Sanchez Spitman, A. B., Moes, D. J. A. R., Gelderblom, H., Dezentje, V. O., Swen, J.J., Guchelaar, H. J.
Publicado 2017

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy

por Sanchez-Spitman, A. B., Dezentjé, V. O., Swen, J. J., Moes, D. J. A. R., Gelderblom, H., Guchelaar, Henk-Jan
Publicado 2018

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse

por Sanchez-Spitman, A. B., Swen, J. J., Dezentjé, V. O., Moes, D. J. A. R., Gelderblom, H., Guchelaar, H. J.
Publicado 2021

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19

por Swen, J. J., van der Straaten, T., Wessels, J. A. M., Bouvy, M. L., Vlassak, E. E. W., Assendelft, W. J. J., Guchelaar, H.-J.
Publicado 2011

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer

por Souwer, E. T. D., Sanchez-Spitman, A., Moes, D. J. A. R., Gelderblom, H., Swen, J. J., Portielje, J. E. A., Guchelaar, H. J., van Gelder, T.
Publicado 2023

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients

por Moes, D. J. A. R, van der Bent, S. A. S, Swen, J. J., van der Straaten, T., Inderson, A., Olofsen, E., Verspaget, H. W., Guchelaar, H. J., den Hartigh, J., van Hoek, B.
Publicado 2015

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation

por Moes, D J A R, Swen, J J, den Hartigh, J, van der Straaten, T, van der Heide, J J Homan, Sanders, J S, Bemelman, F J, de Fijter, J W, Guchelaar, H J
Publicado 2014